Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Darunavir - Janssen R&D Ireland

Drug Profile

Darunavir - Janssen R&D Ireland

Alternative Names: Prezista; TMC-114; Virem

Latest Information Update: 13 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tibotec Pharmaceuticals
  • Developer Gilead Sciences; Janssen R&D Ireland
  • Class Antiretrovirals; Carbamates; Furans; Sulfonamides
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV infections
  • New Molecular Entity Yes
  • Available For Licensing Yes - HIV infections; HIV-1 infections

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 29 Mar 2023 Phase-II/III clinical trials in HIV-1 infections (In adolescents, In children, In infants, Treatment-experienced) in Zimbabwe (PO) before March 2023 (NCT02016924)
  • 19 Feb 2023 Efficacy, adverse events and pharmacokinetic data from the phase II/III trial were presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI-2023)
  • 01 Apr 2021 Janssen Research & Development completes a phase I trial (In volunteers, Combination therapy) in Belgium (PO) (NCT04208061)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top